Connor, Clark & Lunn Investment Management (CC&L)’s Xeris Biopharma Holdings XERS Stock Holding History

Connor, Clark & Lunn Investment Management (CC&L)’s Portfolio XERS Stock Details XERS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.01M	Sell	127,107 -280,518	-69%	-$1.79M	﹤0.01%	1191
2026 Q1	$2.36M	Sell	407,625 -651,067	-61%	-$4.32M	0.01%	913
2025 Q4	$8.31M	Sell	1,058,692 -640,065	-38%	-$5.04M	0.02%	510
2025 Q3	$13.8M	Buy	1,698,757 +470,798	+38%	+$3.13M	0.04%	338
2025 Q2	$5.73M	Buy	1,227,959 +638,488	+108%	+$2.93M	0.02%	536
2025 Q1	$3.24M	Buy	589,471 +418,139	+244%	+$1.69M	0.01%	607
2024 Q4	$581K	Buy	171,332 +88,224	+106%	+$284K	﹤0.01%	1105
2024 Q3	$237K	Buy	+83,108	New	+$213K	﹤0.01%	1294
2022 Q2	–	Sell	-28,897	Closed	-$74K	–	1219
2022 Q1	$74K	Buy	+28,897	New	+$70.6K	﹤0.01%	990

Other funds holding XERS

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

Rosalind Advisors Toronto, Ontario, Canada $269M AUM 103.38% 1-Year Est. Return

Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Connor, Clark & Lunn Investment Management (CC&L)'s XERS Position: Q2 2026 in Review

Connor, Clark & Lunn Investment Management (CC&L) reduced its Xeris Biopharma Holdings (XERS) stake by 69% in Q2 2026, selling an estimated $1.79M and leaving 127,107 shares worth $1.01M. The position accounts for ﹤0.01% of the portfolio, ranked #1191.

Connor, Clark & Lunn Investment Management (CC&L) first reported a position in XERS in Q1 2022 and has held it in 9 quarters since. The position peaked at $13.8M in Q3 2025. 239 funds tracked by Wall St. Rank hold XERS as of Q2 2026.

Connor, Clark & Lunn Investment Management (CC&L) held 127,107 shares of Xeris Biopharma Holdings worth $1.01M as of Q2 2026.
Connor, Clark & Lunn Investment Management (CC&L) sold 280,518 Xeris Biopharma Holdings shares in Q2 2026, an estimated $1.79M.
Xeris Biopharma Holdings made up ﹤0.01% of Connor, Clark & Lunn Investment Management (CC&L)'s portfolio in Q2 2026, its #1191 holding.
Connor, Clark & Lunn Investment Management (CC&L) first reported a position in Xeris Biopharma Holdings in Q1 2022 and has held it in 9 quarters since.
Connor, Clark & Lunn Investment Management (CC&L)'s Xeris Biopharma Holdings position peaked at $13.8M in Q3 2025.
239 funds tracked by Wall St. Rank held Xeris Biopharma Holdings as of Q2 2026.

Based on Connor, Clark & Lunn Investment Management (CC&L)'s 13F filing for Q2 2026, filed 13 Aug 2026.